E Merck fuses French orthopaedic units:
This article was originally published in Clinica
Executive Summary
E Merck has merged two of its French companies, Prothaid and Impact, to create Merck Biomaterial France. The new company, which hopes to gain 14% of the French orthopaedic market this year, is expected to have an annual turnover of around Fr 160 million ($32.6 million). E Merck acquired Prothaid, specialising in ligament prostheses, last February (see Clinica No 643, p 11) and has now merged it with Impact, which produces joint prostheses. The German company invested Fr 80 million in a manufacturing plant in Valence, while commercial and marketing activities will continue to be carried out in Bordeaux, Levallois and Charnoz.